| 刘景勤,邢思思,王月,施晓星,许纯纯,王海婷.放射治疗联合替西罗莫司治疗中晚期肾癌的临床观察[J].中国临床保健杂志,2017,20(6):734-737. |
| 放射治疗联合替西罗莫司治疗中晚期肾癌的临床观察 |
| Clinical observation of radiotherapy combined with temsirolimus for mid and late stage kidney cancer |
| 投稿时间：2017-07-20 |
| DOI：10.3969/J.issn.1672-6790.2017.06.031 |
| 中文关键词: 肾肿瘤 放射疗法 免疫抑制剂 |
| 英文关键词: Kidney neoplasms Radiotherapy Immunosuppressive agents 〖FL |
| 基金项目: |
|
| 摘要点击次数: 6445 |
| 全文下载次数: 4108 |
| 中文摘要: |
| 目的 评估放疗联合替西罗莫司治疗方案在中晚期肾癌临床治疗中的疗效及安全性。方法 将入选的73例中晚期肾癌患者采用随机数字表法分为两组,即对照组 (36例) 和治疗组 (37例)。对照组采用放射治疗,照射剂量为200 cGy/d,每周照射5 d,5周为1个治疗周期,每个周期照射总剂量为5000 cGy；治疗组患者在放射治疗的基础上,配合250 mL氯化钠溶液给予静脉滴注替西罗莫司治疗,20 毫克/次,静脉滴注60 min,每周2次,5周为一个治疗周期。在治疗前、完成一个治疗周期后,分别对患者的临床疗效、生活质量进行评估,检测患者血清肿瘤标志物水平的变化,同时观察并记录两组患者治疗过程中出现的毒性作用。结果 完成一个周期治疗后,与对照组患者相比,治疗组患者的治疗显效率为32.43%、治疗有效率为72.97%,均显著高于对照组患者的13.89%和41.67% (P<0.05)；治疗组患者的躯体功能、角色功能、情感功能、认知功能、社会功能等功能项目的评分在接受治疗后均明显改善,且改善程度明显优于对照组患者(P<0.05)；治疗后,治疗组患者血清中神经元特异性烯醇化酶、糖类癌抗原125、癌胚抗原、铁蛋白、β2-微球蛋白等肿瘤标志物的水平明显降低,且显著低于对照组患者的相应指标(P<0.05)；此外,在治疗过程中,两组患者均有数例出现中度或重度不良反应,但治疗组患者中出现疲弱、困倦、脱发、恶心呕吐、关节疼痛、肝损伤、白细胞减少症等不良反应的发生率均显著低于对照组患者(P<0.05)。结论 放疗联合替西罗莫司的治疗方案用于中晚期肾癌的临床治疗,在改善患者病情、提高患者生活质量、改善患者血清肿瘤标志物水平等方面都能够取得良好效果,而且不良反应发生率较低。 |
| 英文摘要: |
| Objective To evaluate the clinical efficacy and safety of radiotherapy combined with Temsirolimus for mid and late stage kidney cancer.Methods Seventy-three patients with mid and late stage renal cell carcinoma were collected and randomly divided into two groups:control group (36 cases) and treatment group (37 cases).The patients of control group were treated with radiation therapy,radiation dose was 200 cgy/day and radiation is given 5 days a week for 5 weeks,total dose irradiation was 5000cgy;patients in the treatment group were treated with intravenous infusion of ticillimerol with 250 ml of sodium chloride solution on the basis of radiotherapy,ticillimerol was given 2 times per week for 5 weeks.The clinical effect and life quality of were evaluated,and the tumor markers were detected; and the appeared side reaction during treatment was recorded of two groups before and after treatment.Results The improvement rate and effective rate of treatment group was 32.43% and 72.97% respectively,which were significantly higher than that of control group (13.89% and 41.67%),P<0.05.After treatment,The physical function,role function,emotional function,cognitive function and social function of treatment group patients were significantly improved after treatment,and improvement were obviously better than those in the control group (P<0.05).The carbohydrate antigens CA125,carcinoembryonic antigen,Ferritin and beta 2-microglobulin were significantly decreased after treatment,and reduction were obviously better than those in the control group(P<0.05).In addition,several cases in two groups patients suffered from moderate or severe adverse reactions in the process of treatment,the incidence rate of weakness ,drowsiness,hair loss,nausea,vomiting,joint pain,liver damage and white blood cells reduce disease were significantly lower than that of control group (P<0.05).Conclusion Radiotherapy combined with temsirolimus for mid and late stage kidney cancer could significantly promote the patients′ treatment efficiency,improve patients′ quality of life,decrease the level of serum tumor markers with less adverse reactions. |
|
查看全文
|
| 关闭 |
|
|
|